Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 20 for “"KRASG12C"”.
-
Investigating KRASG12C driven tumorigenesis and targeted therapy in colorectal cancer
Abstract not currently available.
-
Interrogating therapeutic resistance to oncogenic KRASG12C-based therapies in colorectal cancer
… of novel covalent inhibitors selective for KRASG12C mutation have entered the clinic, which has not only marked a major milestone in cancer drug discovery but has also intensified efforts to directly target other KRAS mutations that have also successfully entered the clinic. However, …
-
Aquaporin 4 promotes Drug Tolerance to AMG 510 in KRASG12C mutant Non-Small Cell Lung Cancer
… there has been a recent development of KRASG12C inhibitors that directly target mutant KRAS, thereby arresting its proliferative effects. A recently FDA-approved KRASG12C inhibitor for the treatment of non-small cell lung cancer, Sotorasib (AMG 510), has been shown to produce …
-
Targeting DNA damage repair with novel DNA-PK inhibitor, BCCA7693 to delay krasg12c inhibitor resistance: balancing cell intrinsic efficacy and immune antagonism
Treatment resistance remains a major barrier in the treatment of KRAS-mutated lung cancers and despite the effectiveness of combinatorial strategies, including MEK inhibitor trametinib and KRASG¹²C inhibitor adagrasib, at suppressing MAPK signalling and slowing tumour growth, the emergence of drug …
-
Refinement of 3D lung cancer models for automation and patient stratification with mode-of-action studies
… from glycine to cysteine in codon 12 (KRASG12C). Being considered “undruggable” in previous decades, KRASG12C-inhibitors now paved the way into the standard-of-care for lung adenocarcinoma treatment in the clinics. Still, the overall response rates as well as overall survival of …
-
Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer
… (multi-kinase), crizotinib (ALK) and sotorasib (KRASG12C) was investigated in vitro in HER-driven gastroesophageal, lung, pancreatic and head and neck cancer cell lines by proliferation, apoptosis, migration assays and signalling analysis. Neratinib-sotorasib was further evaluated in 3D spheroids …
-
Σηματοδοτικό μονοπάτι του kras στον ΜΜΚΠ: Θεωρητική προσέγγιση και θεραπευτικές στρατηγικές
… του Kras, και πιο συγκεκριμένα της μετάλλαξης KrasG12C, σοτορασίμπης και ανταγκρασίμπης. Ο ρόλος του Kras στη κυτταρική σηματοδότηση είναι κομβικός για το τελικό αποτέλεσμα που είναι η επιβίωση, ο πολλαπλασιασμός, η απόπτωση, η μετανάστευση του κυττάρου όταν το σήμα φτάσει στον πυρήνα. Η …
-
Dissecting KRAS Functional Heterogeneity in Patient-Derived Lung Adenocarcinoma Models
… XDOs and evaluated the novel class of GDP-KRASG12C inhibitors in both XDO and PDX models, studied its short-term pharmacodynamic effects on tumor gene expression and protein signaling, and identified mechanisms of intrinsic resistance to these compound as well as methods of overcoming this …
-
Modulation of important non-coding RNAs and proteins in cancer with role in transcription and translation initiation regulation
… their deregulation. To decipher the effects of KRASG12C on transcription and translation initiation in lung adenocarcinoma, generation of TetON-inducible KRASG12C stable A549 and CL1-5 cell lines using TALENs was performed. Further examination of the two cell lines revealed that in CL1-5 cells, …
-
Functional contribution of epithelial to mesenchymal transition program on KRASG12D targeting efficacy in pancreatic cancer
… known for their low efficacy. The emergence of KRASG12C inhibitors, Adagrasib and Sotorasib, paved the way for the development of MRTX1133, a KRASG12D inhibitor. Although MRTX1133 improved survival outcomes in pre-clinical resistance to KRASG12D inhibition develops after prolonged treatment. As …
-
An in vivo inflammatory loop potentiates KRAS blockade
… carboxylmethyltransferase), and AA12 (targeting KRASG12C), and silenced/overexpressed mutant KRAS using custom vectors. We show that KRAS-mutant tumor cells exclusively respond to KRAS blockade in vivo, because the oncogene co-opts host myeloid cells via a C-C-motif chemokine ligand …
-
Therapeutic Targeting of Protocadherin 7 in Lung Adenocarcinoma
… tyrosine kinase inhibitor Osimertinib, and the KRASG12C inhibitor Adagrasib. Moreover, a humanized mAb7 decreased tumor growth in an Fc-dependent manner and enhanced antibody dependent cell-mediated cytotoxicity and granzyme B production. These findings provide an important step towards the …
-
Targeting drug resistant lung adenocarcinoma through hyperactivation of oncogenic pathways
… a model of trametinib resistance, I found that KRASG12C amplification resulted in a “drug addicted” phenotype, whereby trametinib removal caused ERK hyperactivation lethal to cells. In models of osimertinib resistance, I profiled the potential of multiple genes to induce ERK hyperactivation. I …
-
Mutant Kras Alters Extracellular Vesicle Microrna Sorting In Pancreatic Cystic Neoplasms
… KRAS, remains largely undruggable, except for KRASG12C mutations, which may be inhibited by sotorasib. Activating mutations in the oncogene KRAS are believed to be the earliest genetic mutation in the development of this disease, occurring in up to 95% of PDACs and 60% of mucinous cysts. While …
-
Synthesis and selection of novel phosphoester oligomers to inhibit the interaction between KRASG12D and RAF1
… leading to tumour formation. Currently, only KRASG12C has clinically approved small molecule inhibitors, which covalently modify the cysteine at position 12, but there is no way to directly inhibit other more prevalent mutations (for example KRASG12D), and a new approach is needed to target …
-
Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom
… langanhaltender Therapieeffekt bei Patienten mit KRASG12C/TP53-Komutationen kontrastiert mit teils erheblich reduziertem Überleben im Falle anderer molekularer Konstellationen. Eine prognostische Einschätzung scheint somit durch ein fokussiertes Genpanel möglich zu sein, welches bereits jetzt im …
-
Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
… resistance rapidly emerged. Additionally, KRasG12C mutations are rare in PDAC, with less than 5% of the reported cases showing this mutation. Therefore, despite promising candidates being reported, the development of new and innovative targeted therapies is still urgently needed.</p> …
-
The Role of METTL21A in Kras-driven Cancers
… sensitivity of METTL21A depletion cells to the KrasG12C inhibitor, AMG510, treatment. The results suggest that METTL21A-depleted cells were more sensitive to AMG510. Interestingly, there is a synergistic effect between Pifithrin-μ and AMG510 for METTL21A depletion cells. Together, these results …
-
Ανάλυση τεκμηρίων στον ορθοκολικό καρκίνο και αντίκτυπος στην κλινική πράξη
… Study 4: the use of targeted therapy against the KRASG12C mutation in metastatic colon and rectal cancer appears promising. However, there was heterogeneity between the studies analyzed.
-
Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer
The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication …